Cargando…
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin’s pharmacokinetics (PKs) and s...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841463/ https://www.ncbi.nlm.nih.gov/pubmed/34706161 http://dx.doi.org/10.1111/cts.13174 |
_version_ | 1784650842532478976 |
---|---|
author | Miao, Jia Fu, Ping Ren, Shuang Hu, Chao Wang, Ying Jiao, Chengfeng Li, Ping zhao, Yu Tang, Cui Qian, Yuli Yang, Rong Dong, Yanli Rong, Jing Wang, Yaohui Jin, Xiaowei Sun, Yu Chen, Li |
author_facet | Miao, Jia Fu, Ping Ren, Shuang Hu, Chao Wang, Ying Jiao, Chengfeng Li, Ping zhao, Yu Tang, Cui Qian, Yuli Yang, Rong Dong, Yanli Rong, Jing Wang, Yaohui Jin, Xiaowei Sun, Yu Chen, Li |
author_sort | Miao, Jia |
collection | PubMed |
description | Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin’s pharmacokinetics (PKs) and safety, and to guide appropriate clinical dosing in patients with diabetic kidney disease, including end‐stage renal disease (ESRD). Based on the results from physiologically‐based pharmacokinetic modeling, the predicted outcome of RI on dorzagliatin PK property would be minimum that the plasma exposure area under concentration (AUC) of dorzagliatin in patients with ESRD would increase at about 30% with minimal change in peak concentration (C(max)) comparing to those in healthy volunteers (HVs). To definitively confirm the prediction, a two‐part RI study was designed and conducted based on regulatory guidance starting with the patients with ESRD matched with HVs. Results of the RI study showed minimum difference between patients with ESRD and HVs with respect to dorzagliatin exposure with geometric mean ratio of ESRD to HV at 0.81 for C(max) and 1.11 for AUC. The elimination half‐life, volume of distribution, and systemic clearance for dorzagliatin were similar between the two groups. Dorzagliatin was well‐tolerated in patients with ESRD during the study. Therefore, RI showed no significant impact on dorzagliatin PK, suggesting that dorzagliatin can be readily used in patients with T2D at all stages of RI without need for dose adjustment. |
format | Online Article Text |
id | pubmed-8841463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88414632022-02-22 Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator Miao, Jia Fu, Ping Ren, Shuang Hu, Chao Wang, Ying Jiao, Chengfeng Li, Ping zhao, Yu Tang, Cui Qian, Yuli Yang, Rong Dong, Yanli Rong, Jing Wang, Yaohui Jin, Xiaowei Sun, Yu Chen, Li Clin Transl Sci Research Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin’s pharmacokinetics (PKs) and safety, and to guide appropriate clinical dosing in patients with diabetic kidney disease, including end‐stage renal disease (ESRD). Based on the results from physiologically‐based pharmacokinetic modeling, the predicted outcome of RI on dorzagliatin PK property would be minimum that the plasma exposure area under concentration (AUC) of dorzagliatin in patients with ESRD would increase at about 30% with minimal change in peak concentration (C(max)) comparing to those in healthy volunteers (HVs). To definitively confirm the prediction, a two‐part RI study was designed and conducted based on regulatory guidance starting with the patients with ESRD matched with HVs. Results of the RI study showed minimum difference between patients with ESRD and HVs with respect to dorzagliatin exposure with geometric mean ratio of ESRD to HV at 0.81 for C(max) and 1.11 for AUC. The elimination half‐life, volume of distribution, and systemic clearance for dorzagliatin were similar between the two groups. Dorzagliatin was well‐tolerated in patients with ESRD during the study. Therefore, RI showed no significant impact on dorzagliatin PK, suggesting that dorzagliatin can be readily used in patients with T2D at all stages of RI without need for dose adjustment. John Wiley and Sons Inc. 2021-11-11 2022-02 /pmc/articles/PMC8841463/ /pubmed/34706161 http://dx.doi.org/10.1111/cts.13174 Text en © 2021 Hua medicine (Shangai) Ltd. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Miao, Jia Fu, Ping Ren, Shuang Hu, Chao Wang, Ying Jiao, Chengfeng Li, Ping zhao, Yu Tang, Cui Qian, Yuli Yang, Rong Dong, Yanli Rong, Jing Wang, Yaohui Jin, Xiaowei Sun, Yu Chen, Li Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator |
title | Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator |
title_full | Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator |
title_fullStr | Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator |
title_full_unstemmed | Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator |
title_short | Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator |
title_sort | effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841463/ https://www.ncbi.nlm.nih.gov/pubmed/34706161 http://dx.doi.org/10.1111/cts.13174 |
work_keys_str_mv | AT miaojia effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT fuping effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT renshuang effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT huchao effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT wangying effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT jiaochengfeng effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT liping effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT zhaoyu effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT tangcui effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT qianyuli effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT yangrong effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT dongyanli effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT rongjing effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT wangyaohui effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT jinxiaowei effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT sunyu effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator AT chenli effectofrenalimpairmentonthepharmacokineticsandsafetyofdorzagliatinanoveldualactingglucokinaseactivator |